HPV/Cervical Pre-cancer and Cancer Surveillance (HPV-Impact)

Overview

In 2006, the introduction of a highly effective vaccine against human papillomavirus (HPV) exposed the need for population-based surveillance of HPV-related diseases. In 2007, the Centers for Disease Control and Prevention funded a collaboration between CEIP and the California Department of Public Health STD Control Branch to conduct surveillance of cervical pre-cancer including cervical intraepithelial neoplasia (CIN) 2/3 and adenocarcinoma in situ (AIS). This surveillance effort is ongoing in Alameda County, California in partnership with the Alameda County Department of Public Health and the California Cancer Registry.

Objectives

• Determine the burden of CIN 2/3, AIS, and cervical cancer in Alameda County and monitor trends in incidence
• Conduct HPV testing for a subset of cases to monitor HPV types
• Monitor and evaluate the impact of the HPV vaccines

Laboratory Reporting

High-grade cervical pre-cancer and cervical cancer is reportable in Alameda County. Please see additional information on reporting eligible cases.

Infographic

In the News

• Just published: Trends in Cervical Precancers Identified Through Population-Based Surveillance in February 27, 2025 Morbidity and Mortality Weekly Report (MMWR)
  • • CDC report adds to evidence that HPV vaccine is preventing cervical cancer in US women | AP News
    • U.S. Sees Huge Drop in Cervical Precancers | MedPage Today
• International HPV Awareness Day and the “One Less Worry” campaign offers resources and social media for patients, providers, and partners
• Get yourself tested for STI’s with a free at-home kit!
• Make history and eliminate cervical cancer for ever, urges WHO chief
  Cervical cancer is the second most common cause of cancer death in reproductive-aged women globally, according to the UN health agency, yet preventable with vaccination and screening that includes appropriate follow-up and treatment. Read more about the Global Strategy to Accelerate the Elimination of Cervical Cancer.
• Principal Investigator Dr. Ina Park’s book Strange Bedfellows: Adventures in the Science, History, and Surprising Secrets of STDs  is available online and in most bookstores. Listen to interviews from her virtual book tour here.
•  

National Collaborating Surveillance Sites

• • Connecticut Emerging Infections Program, Yale University

• • Tennessee Emerging Infections Program, Tennessee Department of Health,  Vanderbilt University

• • New York Emerging Infections Program, University of Rochester
  • Oregon Emerging Infections Program, Oregon Health Authority

Questions?

Please contact:

• Ina Park, MD MS
  Principal Investigator
  Associate Professor, UCSF School of Medicine
  ina.park@ucsf.edu
• Erin Whitney, MPH
  HPV Surveillance Project Coordinator
  STD Control Branch, California Department of Public Health
  850 Marina Bay Parkway, Bldg P, 2nd Floor
  Richmond, CA 94804
  erin.whitney@cdph.ca.gov
  (510) 620-2379

Links

For more information on HPV and the HPV vaccine:

• The CDC’s HPV-Impact Page
• The American Sexual Health Association’s HPV Website
• Published HPV-Impact articles on PubMed.gov
• The Centers for Disease Control and Prevention HPV Page
• California Department of Public Health Human Papillomavirus Page
• Advisory Committee on Immunization Practices (ACIP) Recommendations for the HPV Vaccine
• CDC’s Adolescent HPV Vaccination Coverage Dashboards